Effect of Probiotics on Viral Pneumonia

Viral Pneumonia Clinical Trial

Official title:

Effect of Probiotic WecProB on the Course of Viral Pneumonia in Children

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06348095
• Other study ID #: WK2024004
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 7, 2024
• Est. completion date: December 31, 2024

Study information

• Verified date: April 2024
• Source: Wecare Probiotics Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the effectiveness and safety of compound probiotic in shortening the course of illness in children with viral pneumonia, in comparison with placebo.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 72
• Est. completion date: December 31, 2024
• Est. primary completion date: October 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 3 Years

Eligibility

Inclusion Criteria:

1. Meet the diagnostic criteria for pneumonia in "Zhufutang Practical Pediatrics" (7th Edition), and the rapid test of nasopharyngeal secretions is positive for RSV, and the diagnosis is confirmed as RSVP;

2. Infants and young children aged 6 months to 3 years;

3. The course of the disease is <48 h;

4. The family members of the children are informed about the study and sign the informed consent form.

Exclusion Criteria:

1. Previous history of wheezing;

2. Cardiovascular disease and congenital tracheal dysplasia;

3. pneumonia induced by other causes;

4. Dysplasia of bronchial and pulmonary tracts;

5. premature infants;

6. Combined with immunosuppressive diseases;

7. Presence of mental illness.

Related Conditions & MeSH terms

• Pneumonia
• Pneumonia, Viral
• Viral Pneumonia

Intervention

Dietary Supplement:
• Probiotic
The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
• Placebo
The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Wecare Probiotics Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Respiratory syncytial virus (RSV) viral load	Viral load was detected by real-time quantitative RT-PCR	7 days